PBE241220P71000
- 0.00
- 0.000.00%
Invesco Biotechnology & Geno Funds Newsroom
Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Exelixis Provides Regulatory Update Related To Supplemental New Drug Application For Cabozantinib; Alliance For Clinical Trials In Oncology Independent Data And Safety Monitoring Board Recommends Trial Enrollment To Be Stopped
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Amgen Decline on MariTide Data Could Be Due to Lack of More Details
4 Stocks to Watch on Tuesday: AMGN, BBY and More
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
How Is The Market Feeling About United Therapeutics?
Amgen's weight loss drug can reduce weight by 20% in one year, but Wall Street is still not satisfied, causing a sharp drop in stock prices.
① The experimental obesity treatment drug MariTide from the usa pharmaceutical company amgen can help obese patients lose an average of up to 20% of their weight after one year of use, but the stock price plummeted due to data falling short of Wall Street expectations. ② Amgen claims that MariTide can lead to faster weight loss, maintain weight, and require fewer injections, but analysts question its potential side effects on bone density.
Amgen Shares Are Trading Lower Following the Results of Its Phase 2 Study With MariTide in Obesity.
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau
Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test.
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
TG Therapeutics Analyst Ratings
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Viking Therapeutics a New Buy at B Riley on Lead Obesity Asset VK2735